September 2021

Orphalan announces FDA acceptance for filing of New Drug Application (NDA) for trientine tetrahydrochloride (TETA 4HCl) for the treatment of Wilson’s Disease

Orphalan announces FDA acceptance for filing of New Drug Application (NDA) for trientine tetrahydrochloride (TETA 4HCl) for the treatment of Wilson’s Disease —NDA supported by positive data from Phase 3 CHELATE clinical trial — TETA 4-HCl previously granted Orphan Drug Designation for first-line treatment of Wilson’s Disease Paris, France – 2 September

>

Publication relating to transparency notifications

PRESS RELEASE REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), September 1, 2021, 10.30pm CET / 4.30pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received two transparency notifications as detailed below. Robelga SRL / Robert Taub On August 27,

>

CORONAVIRUS/Taiwan reports 5 new COVID-19 cases, 1 death

Taiwan on Thursday reported five new COVID-19 cases — all but one contracted overseas — and one death from the disease, according to the Central Epidemic Command Center (CECC).The new cases bring the total in Taiwan to 16,006, of which 14,365 are dom…

>

Taiwan shares close down 0.88%

Taiwan shares closed down 154.23 points, or 0.88 percent, at 17,319.76 Thursday on turnover of NT$347.36 billion (US$12.54 billion).Source: Focus Taiwan News Channel

>